Investors

Investors

Astrazeneca First-Half 2015 Results

AstraZeneca announced first-half 2015 results on Thursday, 30 July which can be found at http://www.astrazeneca.com/Investors/financial-information/Financial-results.

A recording of the analyst presentation and Q&A session will be available until 13:30BST Wednesday 12 August, on the following numbers:

UK (freephone): 0800 953 1533
International: +44 1452 55 00 00
US (freephone): 1 866 247 4222

Conference ID: 75191806
 


American Society of Clinical Oncology (ASCO) Annual Meeting

1 June 2015

AstraZeneca will be hosting a briefing for analysts and investors during the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago on Monday 1 June 2015, from 8:30pm –10:00pm CDT (2 June 2:30am - 4:00am BST – UK). The aim of this event is to update on progress with AstraZeneca’s immuno-oncology pipeline and combination treatments.

You will be able to listen to the event using the following dial in details:

UK freephone: 0800 694 0257
US freephone: 866 966 9439
Sweden freephone: 0200 890171
International: +44 (0) 1452 555566

Conference code: 42762226

Listen to webcast


Latest downloads

ASCO 2015 Investor science event

1 June 2015

ASCO 2015 Investor science event biographies

1 June 2015

AstraZeneca Mölndal

22 May 2015

First quarter results 2015

24 April 2015

Investor science conference call ACC 2015

16 March 2015

AstraZeneca refines its financial reporting in line with evolving business model

6 March 2015

Investor Relations presentation - March 2015

5 March 2015

Fourth quarter and full year results 2014

5 February 2015

Latest press releases

AstraZeneca to update on leading lung cancer portfolio at WCLC 2015
4 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
3 September 2015
Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
2 September 2015
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
2 September 2015
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
1 September 2015
PEGASUS-TIMI 54 sub-analysis shows importance of continuing treatment with BRILINTA beyond one year following a heart attack
31 August 2015
AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015
29 August 2015
AstraZeneca appoints Dr Sean Bohen as Executive Vice President of Global Medicines Development and Chief Medical Officer
24 August 2015
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial
24 August 2015
Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals
10 August 2015
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
6 August 2015
MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
5 August 2015

Share price

London
41.82 GBP
New York
31.70 USD
Stockholm
538.50 SEK

At 5-9-2015 15:12 GMT

Detailed share price


Stock symbol - AZN

On LSE, NYE and OMX